Evidence map›Paper›PMID 37927416›Full record

ArticleOncology letters2023

Clinical activity of crizotinib in lung adenocarcinoma harboring a

Ryosuke Kinoshita, Makoto Nakao, Hiroko Kiyotoshi, Syuntaro Hayashi, Masahiro Sugihara, Yuya Hirata, Mamiko Kuriyama, Norihisa Takeda, Hideki Muramatsu

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 63% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ryosuke KinoshitaDepartment of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Aichi 498-8502, Japan.
Makoto NakaoDepartment of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Aichi 498-8502, Japan.
Hiroko KiyotoshiDepartment of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Aichi 498-8502, Japan.
Syuntaro HayashiDepartment of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Aichi 498-8502, Japan.
Masahiro SugiharaDepartment of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Aichi 498-8502, Japan.
Yuya HirataDepartment of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Aichi 498-8502, Japan.
Mamiko KuriyamaDepartment of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Aichi 498-8502, Japan.
Norihisa TakedaDepartment of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Aichi 498-8502, Japan.
Hideki MuramatsuDepartment of Respiratory Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Yatomi, Aichi 498-8502, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The benefits of crizotinib therapy in patients with tyrosine receptor kinase ROS proto-oncogene 1 (

Indexed as

crizotinibHLA_A-ROS1Lung adenocarcinomamultigene panel assay

Identifiers

PMID37927416
PMCPMC10623087
OpenAlexW4387617800

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.